COVID-19 News

NIAID selects Metabolon to join study of biomarkers for COVID-19 outcome

Morrisville, North Carolina-based Metabolon, Inc. will participate in a study funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to determine how the human immune system responds to COVID-19.

The Immunophenotyping Assessment in a COVID-19 Cohort (IMPACC) study, being led by researchers at the Precision Vaccines Program (PVP) at Boston Children’s Hospital, is focused on defining biomarkers of COVID-19 severity and outcome. Metabolon will characterize the impact of SARS-CoV-2, the virus that causes COVID-19, on the human plasma metabolome.

“It’s an honor to collaborate with NIAID and participating researchers across the U.S. on the IMPACC study to assess and precisely characterize the impact of SARS-CoV-2 on health,” said Greg Michelotti, PhD, Scientific Director for Metabolon. “Metabolomics provides a detailed snapshot of the phenotype, enabling deeper understanding of health and disease. The actionable metabolomics insights will help inform development of diagnostics, prognostics, therapeutics and vaccines to address the COVID-19 pandemic.”

This study with NIAID also involves supporting the PVP’s Clinical Data Collection Center (CDCC) in their efforts to integrate clinical data such as age, sex, COVID-19 disease severity and outcomes with systems biology data, including metabolomics.

Dr. Ofer Levy, Director of the PVP at Boston Children’s Hospital said: “We are honored to partner with NIAID and Metabolon in this effort to define how the human response to SARS-CoV-2 correlates to COVID severity and outcome. Metabolic features of the immune responses are increasingly recognized as pivotal to disease and health, and we are fortunate to have Metabolon’s excellent team by our side as we undertake this critical work.”

Metabolomics is fundamental to unlocking the genome and delivering on the promise of multi-omics. The approach supports population health initiatives and gets our world closer to the goal of personalized medicine.

Metabolon will perform global metabolomics on biological samples, including serum, derived from a population of about 1,000 study participants. The samples will be examined across different time points to observe metabolic changes in the immune response to SARS-CoV-2 infection over time and correlate these with COVID severity and outcome.

Read more: https://apnews.com/press-release/pr-newswire/business-science-public-hea...